These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10178683)

  • 1. Single donor platelets: can we afford to use them? Can we afford not to use them?
    Zeger G; Williams CT; Shulman IA
    Transfus Sci; 1997 Dec; 18(4):585-8. PubMed ID: 10178683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets.
    Lopez-Plaza I; Weissfeld J; Triulzi DJ
    Transfusion; 1999 Sep; 39(9):925-32. PubMed ID: 10533816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apheresis platelets: emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose.
    Goodnough LT; Kuter D; McCullough J; Brecher ME
    J Clin Apher; 1998; 13(3):114-9. PubMed ID: 9828021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated platelet collection using the latest apheresis devices in an Indian setting.
    Agarwal P; Verma A
    Transfus Apher Sci; 2009 Oct; 41(2):135-8. PubMed ID: 19709930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and quality evaluation of apheresis vs random-donor platelet concentrates stored for 7 days.
    Hussein E
    Transfus Med; 2015 Feb; 25(1):20-6. PubMed ID: 25808050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled platelet concentrates: maybe not fancy, but fiscally sound and effective.
    Sweeney JD; Petrucci J; Yankee R
    Transfus Sci; 1997 Dec; 18(4):575-83. PubMed ID: 10178682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet function testing during 5-day storage of single and random donor plateletpheresis.
    Akay OM; Gündüz E; Başyiğit H; Gulbas Z
    Transfus Apher Sci; 2007 Jun; 36(3):285-9. PubMed ID: 17602871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of a switch to a 100% apheresis platelet supply for patients and for blood donors: a risk benefit analysis.
    Thiele T; Alt-Mayer T; Greinacher A; Bux J
    Vox Sang; 2016 Nov; 111(4):350-356. PubMed ID: 27432635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet concentrates, from whole blood or collected by apheresis?
    van der Meer PF
    Transfus Apher Sci; 2013 Apr; 48(2):129-31. PubMed ID: 23535511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components.
    Xiao W; Tormey CA; Capetillo A; Maitta RW
    Vox Sang; 2013 Nov; 105(4):334-40. PubMed ID: 23802769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of random-donor platelet concentrates prepared from whole blood units and platelets prepared from single-donor apheresis collections.
    Sloand EM; Yu M; Klein HG
    Transfusion; 1996; 36(11-12):955-9. PubMed ID: 8937403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The collection of platelets by apheresis procedures.
    Simon TL
    Transfus Med Rev; 1994 Apr; 8(2):132-45. PubMed ID: 8003856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets.
    Vamvakas EC
    Clin Lab; 2010; 56(7-8):263-79. PubMed ID: 20857891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of single donor platelets.
    Kirkley SA; Blumberg N
    Blood Rev; 1994 Sep; 8(3):142-7. PubMed ID: 7819816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of PEG-rhuMGDF in platelet apheresis.
    Kuter DJ
    Stem Cells; 1998; 16 Suppl 2():231-42. PubMed ID: 11012195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of leukocyte and platelet administration in cancer therapy.
    Walker EM; Cannon A; Mitchum EN
    Ann Clin Lab Sci; 1983; 13(6):453-73. PubMed ID: 6197928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use?].
    Lozano ML; Rivera J; Vicente V
    Med Clin (Barc); 2012 May; 138(12):528-33. PubMed ID: 21807386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic impact of donor platelet count and platelet yield in apheresis products: relevance for emerging issues in platelet transfusion therapy.
    Goodnough LT; Ali S; Despotis G; Dynis M; DiPersio JF
    Vox Sang; 1999; 76(1):43-9. PubMed ID: 9933853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor selection criteria to maximize double platelet products (DPP) by platelet apheresis.
    Wollersheim J; Dautzenberg M; van de Griendt A; Sybesma B
    Transfus Apher Sci; 2006 Apr; 34(2):179-86. PubMed ID: 16574489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemoglobin and platelet count effect on platelet yields in plateletpheresis.
    Guerrero-Rivera S; Gutiérrez-Espíndola G; Talavera JO; Meillón-García LA; Pedraza-Echevarría M; Pizzuto-Chávez J
    Arch Med Res; 2003; 34(2):120-3. PubMed ID: 12700007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.